Avidity Partners Management L.P. 13F annual report
Avidity Partners Management L.P. is an investment fund managing more than $2.35 trillion ran by Delmer Iii. There are currently 84 companies in Mr. Iii’s portfolio. The largest investments include Intuitive Surgical Inc and Boston Scientific, together worth $199 billion.
$2.35 trillion Assets Under Management (AUM)
As of 7th August 2024, Avidity Partners Management L.P.’s top holding is 245,000 shares of Intuitive Surgical Inc currently worth over $109 billion and making up 4.6% of the portfolio value.
Relative to the number of outstanding shares of Intuitive Surgical Inc, Avidity Partners Management L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 1,170,100 shares of Boston Scientific worth $90.1 billion, whose value grew 15.1% in the past six months.
The third-largest holding is Natera Inc worth $83 billion and the next is Arvinas Inc worth $79.5 billion, with 2,987,845 shares owned.
Currently, Avidity Partners Management L.P.'s portfolio is worth at least $2.35 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Avidity Partners Management L.P.
The Avidity Partners Management L.P. office and employees reside in Dallas, Texas. According to the last 13-F report filed with the SEC, Delmer Iii serves as the Chief Compliance Officer at Avidity Partners Management L.P..
Recent trades
In the most recent 13F filing, Avidity Partners Management L.P. revealed that it had opened a new position in
Incyte and bought 529,000 shares worth $32.1 billion.
This means they effectively own approximately 0.1% of the company.
Incyte makes up
1.9%
of the fund's Health Care sector allocation and has decreased its share price by 4.9% in the past year.
The investment fund also strengthened its position in Intuitive Surgical Inc by buying
19,000 additional shares.
This makes their stake in Intuitive Surgical Inc total 245,000 shares worth $109 billion.
Intuitive Surgical Inc soared 53.8% in the past year.
On the other hand, there are companies that Avidity Partners Management L.P. is getting rid of from its portfolio.
Avidity Partners Management L.P. closed its position in Fusion Pharmaceuticals on 14th August 2024.
It sold the previously owned 6,500,328 shares for $139 billion.
Delmer Iii also disclosed a decreased stake in Boston Scientific by 0.4%.
This leaves the value of the investment at $90.1 billion and 1,170,100 shares.
One of the largest hedge funds
The two most similar investment funds to Avidity Partners Management L.P. are Journey Strategic Wealth and Tiedemann Advisors. They manage $2.35 trillion and $2.35 trillion respectively.
Delmer Iii investment strategy
Avidity Partners Management L.P.’s portfolio is diversified across 5 sectors.
Currently, their heaviest sector is Health Care — making up 72.9% of
the total portfolio value.
The fund focuses on investments in the United States as
63.1% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
20% of the total holdings value.
On the other hand, small-cap stocks make up only 8.3% of the portfolio.
The average market cap of the portfolio companies is close to $28.7 billion.
The complete list of Avidity Partners Management L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Fusion Pharmaceuticals Inc. |
Closed
6,500,328
|
$138,586,993,000 | |
| Intuitive Surgical Inc |
8.41%
245,000
|
$108,988,250,000 | 4.63% |
| Boston Scientific Corp. |
40.18%
1,170,100
|
$90,109,401,000 | 3.83% |
| Natera Inc |
4.58%
766,500
|
$83,004,285,000 | 3.53% |
| Arvinas Inc |
0.09%
2,987,845
|
$79,536,434,000 | 3.38% |
| Acadia Healthcare Company In |
11.44%
1,120,000
|
$75,644,800,000 | 3.21% |
| Dianthus Therapeutics Inc |
7.35%
2,917,231
|
$75,497,938,000 | 3.21% |
| Syndax Pharmaceuticals Inc |
38.24%
3,335,000
|
$68,467,550,000 | 2.91% |
| Neurocrine Biosciences, Inc. |
8.48%
491,000
|
$67,595,970,000 | 2.87% |
| Avantor, Inc. |
14.51%
3,086,000
|
$65,423,200,000 | 2.78% |
| Align Technology, Inc. |
Closed
189,000
|
$61,976,880,000 | |
| Cigna Group (The) |
No change
184,500
|
$60,990,165,000 | 2.59% |
| Jazz Pharmaceuticals plc |
6.76%
544,500
|
$58,114,485,000 | 2.47% |
| Eli Lilly Co |
Closed
70,000
|
$54,457,200,000 | |
| Alnylam Pharmaceuticals Inc |
8.64%
222,000
|
$53,946,000,000 | 2.29% |
| Regeneron Pharmaceuticals, Inc. |
29.41%
48,000
|
$50,449,440,000 | 2.14% |
| Illumina Inc |
3.00%
478,000
|
$49,893,640,000 | 2.12% |
| Tenet Healthcare Corp. |
38.10%
372,000
|
$49,487,160,000 | 2.10% |
| Abbvie Inc |
22.38%
277,800
|
$47,648,256,000 | 2.02% |
| Alpine Immune Sciences Inc |
Closed
1,174,700
|
$46,565,108,000 | |
| Thermo Fisher Scientific Inc. |
118.58%
80,000
|
$44,240,000,000 | 1.88% |
| CVS Health Corp |
Closed
545,000
|
$43,469,200,000 | |
| Structure Therapeutics Inc |
24.42%
1,075,000
|
$42,215,250,000 | 1.79% |
| Blueprint Medicines Corp |
10.09%
383,000
|
$41,279,740,000 | 1.75% |
| Cg Oncology Inc |
10.90%
1,296,225
|
$40,921,823,000 | 1.74% |
| Merck Co Inc |
35.26%
325,000
|
$40,235,000,000 | 1.71% |
| Ultragenyx Pharmaceutical In |
2.84%
960,000
|
$39,456,000,000 | 1.68% |
| IDEAYA Biosciences, Inc. |
39.68%
1,117,000
|
$39,217,870,000 | 1.67% |
| Danaher Corp. |
4.31%
150,000
|
$37,477,500,000 | 1.59% |
| Janux Therapeutics Inc |
118.67%
840,219
|
$35,196,774,000 | 1.50% |
| United Therapeutics Corp |
49.31%
110,000
|
$35,040,500,000 | 1.49% |
| Incyte Corp. |
Opened
529,000
|
$32,067,980,000 | 1.36% |
| Surgery Partners Inc |
9.59%
1,306,477
|
$31,081,088,000 | 1.32% |
| Perspective Therapeutics Inc |
Opened
3,037,668
|
$30,285,550,000 | 1.29% |
| Axsome Therapeutics Inc |
12.76%
376,000
|
$30,268,000,000 | 1.29% |
| Caribou Biosciences Inc |
Closed
5,785,352
|
$29,736,709,000 | |
| Xenon Pharmaceuticals Inc |
6.20%
754,000
|
$29,398,460,000 | 1.25% |
| Dexcom Inc |
46.41%
259,000
|
$29,365,420,000 | 1.25% |
| Revolution Medicines Inc |
18.90%
755,000
|
$29,301,550,000 | 1.25% |
| Insmed Inc |
Opened
430,000
|
$28,810,000,000 | 1.22% |
| Intra-Cellular Therapies Inc |
33.33%
400,000
|
$27,396,000,000 | 1.16% |
| Cullinan Therapeutics Inc |
Opened
1,559,826
|
$27,203,365,000 | 1.16% |
| Glaukos Corporation |
No change
224,000
|
$26,510,400,000 | 1.13% |
| Neurogene Inc |
56.38%
727,537
|
$26,475,071,000 | 1.12% |
| Argenx Se |
Opened
60,500
|
$26,017,420,000 | 1.11% |
| Mirum Pharmaceuticals Inc |
36.03%
731,104
|
$24,996,446,000 | 1.06% |
| Establishment Labs Holdings Inc |
136.00%
531,000
|
$24,128,640,000 | 1.03% |
| Immunovant Inc |
79.80%
908,000
|
$23,971,200,000 | 1.02% |
| Rocket Pharmaceuticals Inc |
7.32%
1,100,000
|
$23,683,000,000 | 1.01% |
| Lantheus Holdings Inc |
39.58%
290,000
|
$23,284,100,000 | 0.99% |
| Vaxcyte, Inc. |
No change
284,000
|
$21,444,840,000 | 0.91% |
| Apogee Therapeutics Inc |
26.53%
487,000
|
$19,163,450,000 | 0.81% |
| Mckesson Corporation |
Closed
33,300
|
$17,877,105,000 | |
| Jasper Therapeutics Inc |
2.89%
782,000
|
$17,751,400,000 | 0.75% |
| Neumora Therapeutics Inc. |
No change
1,800,000
|
$17,694,000,000 | 0.75% |
| Legend Biotech Corp |
40.45%
398,000
|
$17,627,420,000 | 0.75% |
| Gilead Sciences, Inc. |
Opened
255,000
|
$17,495,550,000 | 0.74% |
| Phathom Pharmaceuticals Inc |
6.63%
1,620,000
|
$16,686,000,000 | 0.71% |
| Vera Therapeutics Inc |
Closed
383,500
|
$16,536,520,000 | |
| Astrazeneca plc |
28.13%
205,000
|
$15,987,950,000 | 0.68% |
| Keros Therapeutics, Inc. |
63.66%
343,200
|
$15,684,240,000 | 0.67% |
| Biohaven Ltd |
500.00%
450,000
|
$15,619,500,000 | 0.66% |
| Sanofi |
Opened
315,000
|
$15,283,800,000 | 0.65% |
| Regenxbio Inc |
No change
1,300,064
|
$15,210,749,000 | 0.65% |
| Context Therapeutics Inc |
Opened
7,419,355
|
$14,875,807,000 | 0.63% |
| Exact Sciences Corp. |
Opened
338,500
|
$14,301,625,000 | 0.61% |
| Astria Therapeutics Inc |
Closed
982,000
|
$13,821,650,000 | |
| Privia Health Group Inc |
No change
764,200
|
$13,281,796,000 | 0.56% |
| Cytokinetics Inc |
Closed
166,000
|
$11,638,260,000 | |
| Radnet Inc |
Closed
238,000
|
$11,581,080,000 | |
| Acadia Pharmaceuticals Inc |
Closed
588,500
|
$10,881,365,000 | |
| Newamsterdam Pharma Company |
17.75%
559,300
|
$10,744,153,000 | 0.46% |
| Immunome, Inc. |
No change
873,891
|
$10,574,081,000 | 0.45% |
| Immunic, Inc. |
No change
8,902,972
|
$9,882,299,000 | 0.42% |
| Corbus Pharmaceuticals Hldgs |
Opened
215,600
|
$9,755,900,000 | 0.41% |
| Cybin Inc |
No change
34,884,000
|
$9,453,564,000 | 0.40% |
| Syros Pharmaceuticals Inc. |
No change
1,673,538
|
$8,635,456,000 | 0.37% |
| Cogent Biosciences, Inc. |
124.52%
1,000,706
|
$8,435,952,000 | 0.36% |
| Immunocore Hldgs Plc |
30.17%
200,000
|
$6,778,000,000 | 0.29% |
| Tyra Biosciences Inc |
Opened
373,000
|
$5,964,270,000 | 0.25% |
| Century Therapeutics Inc |
Closed
1,221,555
|
$5,106,100,000 | |
| Kyverna Therapeutics Inc |
Closed
202,333
|
$5,025,952,000 | |
| Emergent Biosolutions Inc |
Closed
1,908,000
|
$4,827,240,000 | |
| UiPath, Inc. |
Opened
362,000
|
$4,590,160,000 | 0.20% |
| Spyre Therapeutics Inc |
Opened
195,000
|
$4,584,450,000 | 0.19% |
| Immatics N.v |
Opened
393,100
|
$4,567,822,000 | 0.19% |
| Ionis Pharmaceuticals Inc |
28.46%
93,000
|
$4,432,380,000 | 0.19% |
| ARCA biopharma Inc |
Opened
1,000,000
|
$3,830,000,000 | 0.16% |
| Editas Medicine Inc |
Opened
816,000
|
$3,810,720,000 | 0.16% |
| Intellia Therapeutics Inc |
Opened
170,000
|
$3,804,600,000 | 0.16% |
| Collegium Pharmaceutical Inc |
67.63%
117,000
|
$3,767,400,000 | 0.16% |
| An2 Therapeutics Inc |
Closed
1,150,000
|
$3,737,500,000 | |
| Prime Medicine Inc |
65.13%
694,000
|
$3,567,160,000 | 0.15% |
| Ginkgo Bioworks Holdings Inc |
Closed
3,000,000
|
$3,480,000,000 | |
| X4 Pharmaceuticals, Inc. |
Closed
2,413,000
|
$3,354,070,000 | |
| AC Immune SA |
81.54%
825,000
|
$3,291,750,000 | 0.14% |
| Kezar Life Sciences Inc |
No change
5,026,000
|
$3,015,600,000 | 0.13% |
| Scynexis Inc |
No change
1,448,728
|
$2,897,456,000 | 0.12% |
| Pacific Biosciences Calif In |
Closed
675,000
|
$2,531,250,000 | |
| Karyopharm Therapeutics Inc |
75.68%
2,018,500
|
$1,751,251,000 | 0.07% |
| Wave Life Sciences Ltd. |
Opened
350,000
|
$1,746,500,000 | 0.07% |
| Kodiak Sciences Inc |
Closed
300,000
|
$1,578,000,000 | |
| Hyperfine Inc |
No change
1,188,178
|
$1,009,951,000 | 0.04% |
| Caremax Inc |
No change
21,200
|
$59,148,000 | 0.00% |
| No transactions found | |||
| Showing first 500 out of 104 holdings | |||
Hedge funds similar to Avidity Partners Management L.P.
- Parsec Management
- Suvretta Capital Management
- Cooperman Leon G
- Krane Funds Advisors
- Frazier Life Sciences Management, L.P.
- Pittenger & Anderson Inc
- Kensico Capital Management Corp
- Journey Strategic Wealth
- Tiedemann Advisors
- Lasalle Investment Management Securities
- Hill Path Capital L.P.
- Ruffer LL.P.
- Beacon Investment Advisory Services, Inc
- Avior Wealth Management